Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26577512.
- Also identified by DOI 10.1016/j.jaad.2015.09.040.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The treatment paradigm for nonmelanoma skin cancer remains surgical. This fact combined with its remarkably high incidence positions it as the fifth most costly cancer to treat in the Medicare population. To address this, consideration of alternative medical therapeutics is warranted. Intralesional 5-fluorouracil is a potentially affordable option that may demand further investigation. This literature review examines current data on its efficacy and adverse effects.
Medical subject headings
- Antimetabolites, Antineoplastic
- Fluorouracil
- Skin Neoplasms